

PLATELET TRANSFUSION REFRACTORINESS

Essay

Submitted for partial fulfillment of the M.Sc. degree
in
Clinical & Chemical Pathology
by

Rowaida Mohamed Adel El Shahat
M.B.B.Ch.

816 . 0756
R. M

Under supervision of

Prof.Dr. Fadila Hassan Sabry
Professor of Clinical Pathology
Ain-Shams University

Ass.Prof.Dr. Salwa Saad Mostafa Khodair
Assistant Professor of Clinical Pathology
Ain-Shams University

Dr. Hanaa Mohamed El Sayed Afifi
Lecturer of Clinical Pathology
Ain-Shams University

Faculty of Medicine
Ain-Shams University
1997

Salwa

Fadila



بسم الله الرحمن الرحيم

قالوا سبحانك لا علم لنا إلا ما علمتنا

إنك أنت العليم الحكيم

صدق الله العظيم

"سورة البقرة-آية ٣٢"

Acknowledgment

First of all thanks to God

This work not have been possible without the help and support of ***Prof.Dr. Fadila Hassan Sabry***, Professor of Clinical and Chemical Pathology, Ain-Shams University, to whom I owe my sincere appreciation for the continuous encouragement and creative push she gave to me.

I owe a great dept to ***Prof.Dr. Salwa Saad Mostafa Khodair***, Assistant Professor of Clinical and Chemical Pathology, Ain-Shams University, who provide valuable expert and constructive criticisms and was enthusiastically following and reviewing this work till the end.

Special and great thanks to ***Dr. Hanaa Mohamed El-Sayed Afifi***, Lecturer of Clinical and Chemical Pathology, Ain-Shams University, who showed extraordinary care and guidance to me all through this work.

To My Parents

To My Husband

To My Daughter

Table of Contents

List of Abbreviations	
List of tables	
Introduction and Aim of the Work	1
Review of Literature	3
Platelet Transfusion	3
• Indications of platelet transfusion	4
• Platelet preparation and storage	14
• Pre-transfusion evaluation	16
• Post- transfusion evaluation	16
Platelet Transfusion Refractoriness	20
• Definition	21
• Frequency of platelet transfusion refractoriness	21
• Causes:	22
I-Immunological factors (platelet factor)	24
– Human leukocyte antigens (HLA)	24
– Platelet specific antigens	34
– Plasma protein antigens	37
II-Non-immunological factors (clinical factors)	39
Major factors	40
Minor factors	42
Prevention of Platelet Transfusion Refractoriness	45
• Non-immune	46
• Allo-immune	48
• Persistently refractory patient	62
Summary	64
References	67
Arabic Summary	

List of Abbreviations

Acute myelogenous leukemia	AML
Adenosine diphosphate	ADP
Allogeneic blood transfusion	ABT
Antigen presenting cell	APC
Anti-thymic globulin	ATG
Corrected count increment	CCI
Differential centrifugation of platelet rich plasma	DC-PRPs
Dimethyl sulphoxide	DMSO
Disseminated intravascular coagulation	DIC
Enzyme linked immunosorbant assay	ELISA
Fibrin degradation product	FDP
Gravt-versus-host disease	GVHD
Human leukocyte antigen	HLA
Immune thrombocytopenia	ITP
Interleukin	IL
Intravenous gamma globulin	IVIgG
Lymphocytotoxicity techniques	LCT
Major histocompatibility complex	MHC
Megakaryocyte colony forming unit	MK-CFU
Methoxypsoralen	MOP
Monoclonal antibody immobilization platelet antigens	MAIPA
Myelodysplastic syndrome	MDS
Neonatal alloimmune thrombocytopenia	NAIT
Non Hodgken's lymphoma	NHL
Paraformaldehyde antibodies	PFA
Platelet concentrates	PCs
Platelet immunofluorescence test	PIFT
Platelet suspension indirect immunofluorescence test	PSIIFT
Platelet radioactive antiglobulin test	P-RAGT
Platelet radioimmunoassay	P-RIA
Platelet rich plasma	PRP
Reticuloendothelial system	RE
Solid phase red blood cell adherence	SPRCA
Tumor necrosis factor	TNF
Veno occlusive disease of the liver	VOD

List of Tables

	PAGE
Table (1): Drug-induced thrombocytopenias	10
Table (2): Pre-transfusion evaluation	16
Table (3): Non-immunological factors (clinical factors)	39
Table (4): Leukofiltration and differential centrifugation of platelet-rich plasma (DC-PRP)	57

